ADC Therapeutics SA
ADCT NYSE· Pharmaceutical Preparations
Last close · Oct 26, 2026
$1.51
KIRA · Stoqly’s AI analyst, in plain words
- ADC Therapeutics SA had $81.4M of revenue in fiscal 2025, up 14.9% on the year before.
- Its operating margin was −149.3%, up 35.1 pts: of every 100 in sales, about −149 is left after running the business.
- ADC Therapeutics SA lost $143M in fiscal 2025.
- Free cash flow was −$141M in fiscal 2025, −173.8% of revenue.
- ADC Therapeutics SA has $258M more cash than debt.
Market cap
$234M
P/E
—
Revenue
$81.4M
Net income
−$143M
Free cash flow
−$141M
Operating margin
−149.3%
ADC Therapeutics SA in 30 seconds · fiscal 2025
Are sales growing?
+14.9%
Yes. Sales grew 14.9% last year.
Does it make a profit?
−175.3%
No. It lost money last year.
Does profit turn into cash?
−173.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What ADC Therapeutics SA does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 10, 2026
- Legal name
- ADC Therapeutics SA
- CIK
- 0001771910
ADC Therapeutics SA · ADCT
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Revenue | $210M | $69.6M | $70.8M | $81.4M |
| Revenue growth | — | −66.9% | 1.8% | 14.9% |
| Gross margin | 98.4% | 96.4% | 91.6% | 92.9% |
| Operating margin | −58.8% | −238.6% | −184.4% | −149.3% |
| Net income | −$157M | −$240M | −$158M | −$143M |
| Net margin | −74.9% | −345.1% | −222.8% | −175.3% |
| Diluted EPS | −$2.01 | −$2.94 | −$1.62 | −$1.12 |
| Cash | ||||
| Cash from operations | −$138M | −$119M | −$124M | −$141M |
| Capital expenditure | $0.7M | $3.2M | $0.9M | $0.3M |
| Free cash flow | −$139M | −$122M | −$125M | −$141M |
| FCF margin | −66.2% | −175.3% | −176.0% | −173.8% |
| Share count change | — | 4.6% | 18.9% | 30.8% |
| Debt and strength | ||||
| Cash and short-term investments | $326M | $279M | $251M | $261M |
| Debt incl. finance leases | — | — | $0.0M | $3.0M |
| Shareholders' equity | $79.5M | −$148M | −$203M | −$186M |
| Current ratio | 5.3x | 5.0x | 3.6x | 4.4x |
| Interest coverage | −3.4x | −3.6x | −2.6x | −2.4x |
| Returns and quality | ||||
| Return on equity | −197.8% | — | — | — |
| Return on tangible equity | −197.8% | — | — | — |
| Piotroski F-score | — | 1 | 3 | 5 |
| Altman Z'' | −4.0 | −10.8 | −14.0 | −14.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$19.6M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
ADC Therapeutics SA · ADCT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.51 a share, the company is worth $234M.
Source: SEC EDGAR XBRL filings (CIK 0001771910). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.